# A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

> **NCT04834778** · PHASE1 · COMPLETED · sponsor: **HiberCell, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Gastric Cancer
- Metastatic Breast Cancer
- Small-cell Lung Cancer
- Other Solid Tumors

## Interventions

- **DRUG:** HC-5404-FU

## Key facts

- **NCT ID:** NCT04834778
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-08
- **Primary completion:** 2023-12-07
- **Final completion:** 2024-01-30
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04834778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04834778, "A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04834778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*